BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, December 23, 2024
See today's BioWorld
Home
» Positive news: Astrazeneca vaccine still effective in B.1.1.7 SARS-CoV-2 variant
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full article
sign up for free
or
sign in
.
Positive news: Astrazeneca vaccine still effective in B.1.1.7 SARS-CoV-2 variant
Feb. 5, 2021
By
Nuala Moran
No Comments
LONDON – A follow-up study of participants in the phase II/III U.K. trial of
Astrazeneca plc
’s COVID-19
vaccine
has shown it remains effective against the new B.1.1.7 variant of SARS-CoV-2.
BioWorld
Clinical
Coronavirus
Vaccine
Europe
